Compugen (CGEN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CGEN Compugen

Watchlist

1.6100
+0.0900+5.92%

Close Nov 27 16:00 ET

1.5501
-0.0599-3.72%

Post 19:57 ET

144.15MMarket Cap53.67P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Compugen Announces USPTO Grants New Patent for Use of COM902
TipRanksNov 27 07:06 ET
Express News | Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use of Com902 (Reduced Fc Anti-Tigit) With Anti-Pd-1 and Anti-Pvrig Antibodies
ReutersNov 27 07:00 ET
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
Seeking AlphaNov 26 06:53 ET
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Yahoo FinanceNov 15 05:11 ET
Truist Financial Maintains Compugen(CGEN.US) With Buy Rating
Moomoo NewsNov 13 07:31 ET · Ratings
Compugen Reports Strong Q3 2024 Results and Progress
TipRanksNov 12 23:22 ET

Comments

Jaguar8

Nov 27 06:03

NEWS

$Compugen (CGEN.US)$
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...

Tsukasa0_0

May 30 22:01

About to Receive Milestone Payment

$Compugen (CGEN.US)$ 🤩
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Moomoo AI

Mar 8 05:18

The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.